Simcere Sanroad

Simcere Sanroad (formerly Beijing Xiangrui Biological Products) is a specialized biopharmaceutical company focused on the discovery, development, and manufacturing of diagnostic and prophylactic solutions for infectious diseases, particularly tuberculosis (TB). Operating as a key subsidiary of the Simcere Pharmaceutical Group, the company is a market leader in China for TB screening with its Tuberculin Purified Protein Derivative (TB-PPD) products. Its portfolio also includes commercialized meningococcal conjugate vaccines and a pipeline of innovative recombinant fusion proteins for TB diagnosis and prevention. Recently, the company has expanded its technological capabilities into the mRNA vaccine field through strategic asset acquisitions. Simcere Sanroad is listed on China's National Equities Exchange and Quotations (NEEQ) and remains a critical player in national public health initiatives.